Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Pipeline
Deals
Financings
Earnings Summary
Stock Summary
Articles
Lianbio
Headquarters:
Shanghai, China
Website:
https://lianbio.com/
Year Founded:
2020
Status:
Public
Industry Sector:
HealthTechnology
CEO:
Adam Leo Stone
Number Of Employees:
N/A
Enterprise Value:
$-80,628,932
PE Ratio:
0.06
Exchange/Ticker 1:
Pink:LIANY
Exchange/Ticker 2:
N/A
Latest Market Cap:
$21,720,300
BioCentury
|
Feb 25, 2025
Deals
Counteroffer from Tang-backed Concentra could scuttle Acelyrin-Alumis: Deals Report
Plus Radiance gets ROR1 ADC from Cspc, Astrazeneca buys Fibrogen’s China subsidiary and more
Read More
BioCentury
|
Feb 17, 2024
Finance
Public equity report: Five follow-ons total $875M+, PIPEs keep flowing
Plus:
LianBio
begins winding down, promises dividend; BioXcel pulls offering
Read More
BioCentury
|
Dec 21, 2023
Management Tracks
Larson leaving LianBio as CFO
Plus: Claypoole becomes CEO of Bioventus, and updates from Boston Pharma, Atlas, Quest, Scribe, 858 and more
Read More
BioCentury
|
Dec 20, 2023
Management Tracks
Abernethy leaving Verily for non-profit
Plus: CEO Wang leaving
LianBio
and more from Bicara and Hervolution, ImPact
Read More
BioCentury
|
Oct 31, 2023
Deals
Oct. 31 Quick Takes: Lilly buying Beam’s opt-in rights for Verve base editing programs
Plus: GSK buys Janssen’s rights to Arrowhead HBV product and more from Galapagos, Sarepta, Amgen,
LianBio
and X4
Read More
BioCentury
|
Oct 25, 2023
Deals
Oct. 24 Quick Takes: BMS buying back Asia rights to mavacamten from LianBio
Plus: Rampart raises $85M series A for DNA-based therapies and updates from Servier, Novartis, Cargo and more
Read More
BioCentury
|
Jul 26, 2023
Finance
July 26 Quick Takes: Versant’s Nexo launches with $60M series A round
Plus: Mirxes raises $50M series D, files for IPO in Hong Kong and updates from Kriya, Kincell, Tarsus, Infinity-MEI
Read More
BioCentury
|
Jun 1, 2023
Data Byte
At least 15 PDUFA dates on FDA’s calendar for June
Expected decisions include BioMarin’s hemophilia A gene therapy, a subQ form of argenx’s of myasthenia gravis drug, and Aldeyra’s retinal cancer candidate
Read More
BioCentury
|
Apr 21, 2023
Management Tracks
Allogene hires former Kite exec Moore
Plus:
LianBio
promotes Pascal to CCO and updates from Ocuphire and ImmVira
Read More
BioCentury
|
Apr 21, 2023
Regulation
April 21 Quick Takes: LianBio’s mavacamten gets priority review in China
Plus: FDA extends PDUFA for Daiichi’s quizartinib, and updates from AbbVie, Apellis and more
Read More
Items per page:
10
1 - 10 of 50
Help Center
Username
Request a Demo
Request Training
Ask a Question
Elevio by Dixa
Help